HC Wainwright Has Negative Estimate for DRTS Q1 Earnings

Alpha Tau Medical Ltd. (NASDAQ:DRTS) – HC Wainwright cut their Q1 2026 EPS estimates for Alpha Tau Medical in a research note issued to investors on Tuesday, March 10th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings per share of ($0.13) for the quarter, down from their prior forecast of ($0.12). HC Wainwright currently has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Alpha Tau Medical’s current full-year earnings is ($0.45) per share. HC Wainwright also issued estimates for Alpha Tau Medical’s Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.13) EPS, Q4 2026 earnings at ($0.13) EPS and FY2026 earnings at ($0.53) EPS.

Alpha Tau Medical (NASDAQ:DRTS) last posted its quarterly earnings data on Wednesday, March 11th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01).

DRTS has been the topic of several other research reports. Zacks Research upgraded Alpha Tau Medical from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 17th. Citigroup lifted their target price on Alpha Tau Medical from $7.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alpha Tau Medical in a research note on Wednesday, January 21st. Finally, Piper Sandler reissued a “neutral” rating and set a $5.00 price target on shares of Alpha Tau Medical in a research report on Wednesday, March 4th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $8.67.

Alpha Tau Medical Stock Down 1.0%

NASDAQ:DRTS opened at $6.97 on Thursday. Alpha Tau Medical has a 52 week low of $2.30 and a 52 week high of $8.60. The stock’s fifty day moving average is $7.05 and its two-hundred day moving average is $5.13. The stock has a market capitalization of $591.20 million, a price-to-earnings ratio of -13.15 and a beta of 1.02.

Institutional Investors Weigh In On Alpha Tau Medical

Several institutional investors have recently added to or reduced their stakes in DRTS. Trifecta Capital Advisors LLC purchased a new position in Alpha Tau Medical in the fourth quarter valued at approximately $48,000. Envestnet Asset Management Inc. acquired a new position in shares of Alpha Tau Medical in the 3rd quarter valued at $62,000. Bank of America Corp DE grew its position in shares of Alpha Tau Medical by 2,779.1% in the 3rd quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock valued at $101,000 after buying an additional 21,677 shares during the last quarter. Wells Fargo & Company MN raised its stake in Alpha Tau Medical by 291.7% during the 4th quarter. Wells Fargo & Company MN now owns 23,500 shares of the company’s stock worth $116,000 after acquiring an additional 17,500 shares in the last quarter. Finally, Millennium Management LLC purchased a new stake in Alpha Tau Medical in the third quarter valued at $170,000. Hedge funds and other institutional investors own 2.65% of the company’s stock.

Alpha Tau Medical News Roundup

Here are the key news stories impacting Alpha Tau Medical this week:

• Positive Sentiment: Citigroup raised its price target on DRTS from $7.00 to $9.00 and maintained a buy view, providing upward valuation pressure and a visible analyst-backed upside case. Citigroup raises price target to $9
• Positive Sentiment: HC Wainwright continues to carry a “Buy” rating and a $12.00 price target on DRTS, supporting longer-term bullish analyst sentiment despite other revisions. Alpha Tau Medical Earns Buy Rating from HC Wainwright
• Neutral Sentiment: Short-interest reports show zero shares shorted for mid-March (days-to-cover 0.0), which looks like a data/reporting anomaly and is unlikely to be a meaningful driver absent corrected figures.
• Negative Sentiment: HC Wainwright cut quarterly and full-year EPS forecasts for FY2026 (now forecasting ~($0.53) FY2026 vs. prior ($0.49)), trimming near-term profitability expectations — a clear negative for short-term sentiment despite the maintained buy rating.
• Negative Sentiment: Alpha Tau reported a recent quarterly EPS miss (reported ($0.14) vs. consensus ($0.13)), which likely weighs on investor confidence and amplifies sensitivity to the downward EPS revisions mentioned above.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.